A Bioequivalence Study of Two Formulations of Ezetimibe and Atorvastatin in Healthy Volunteers

The primary objective of this study is to evaluate the **bioequivalence** of two formulations of **ezetimibe/atorvastatin** in healthy volunteers. This is clinically relevant as establishing bioequivalence ensures that the two formulations can be used interchangeably, maintaining therapeutic efficacy and safety. No secondary objectives are provided for this study.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants is categorized under code "3," which typically includes adults. The trial population was selected to include a vulnerable population, although specific details regarding the selection process or lifestyle considerations such as diet, physical activity, or habits are not provided. The sponsor has not disclosed the total number of participants involved in the study. Key inclusion or exclusion criteria are not specified, and the main objective of the trial is not detailed in the available data.

The clinical trial is designed to evaluate the **bioequivalence** of two formulations of ezetimibe/atorvastatin in **healthy volunteers**. This study is a Phase 2 trial, which will be conducted in a randomized, double-blind, and controlled manner to ensure the reliability and validity of the results. The trial is expected to commence recruitment on March 7, 2025, and is anticipated to conclude by May 28, 2025, marking the overall trial duration.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive one of the two formulations. Throughout the trial, follow-up visits will be scheduled to monitor the participants' health status, adherence to the study protocol, and to collect necessary data for the evaluation of the primary and secondary endpoints. The end-of-study visit will be conducted to perform final assessments and ensure the well-being of the participants before their exit from the study.

The expected length of participant involvement will span the duration of the trial, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include non-compliance with the study protocol, adverse events that compromise participant safety, or withdrawal of consent by the participant. The trial is structured to maintain the highest ethical standards and scientific rigor, ensuring the integrity of the data collected and the safety of all participants involved.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 2 study, which typically focuses on assessing the efficacy of a treatment and further evaluating its safety. The trial is scheduled to commence recruitment on March 7, 2025, with an estimated end date of May 28, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase 2 trials generally involve measuring clinical outcomes that may include symptom improvement scores, biomarker levels, or disease remission rates. These outcomes are often assessed using validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints throughout the study duration. The data collected will be analyzed to determine the treatment's efficacy in the targeted medical condition. The trial's design and methodology will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments.